tailieunhanh - An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitornaïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations

Afatinib is approved globally for EGFR-TKI treatment-naïve patients with EGFR mutation-positive nonsmall cell lung cancer (NSCLC). In this Korean expanded access program, we evaluated its ‘real-world’ safety and efficacy. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN